Cannara Biotech (LOVE) 주식 개요는 자회사와 함께 캐나다에서 대마초 및 대마초 유래 제품의 실내 재배, 가공 및 판매에 종사하고 있습니다. 자세히 보기LOVE 펀더멘털 분석스노우플레이크 점수가치 평가5/6미래 성장5/6과거 실적2/6재무 건전성6/6배당0/6강점공정 가치 추정치보다 낮은 92.2% 에서 거래수익은 매년 59% 증가할 것으로 예상됩니다.분석가들은 주가가 81.5% 상승할 것이라는 데 동의합니다.위험 분석이익 마진 (9.3%)이 지난해 (15.2%)보다 낮습니다.모든 위험 점검 보기LOVE Community Fair Values Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN38.0% undervaluedAnalystLowTarget•16d agoCapacity Expansion And Rising SG&A Will Test Margins Yet Future Exports May Offer Relief803AN41.6% undervaluedAnalystConsensusTarget•3mo agoExpanded Capacity And EU Export Optionality Will Support Long Term Premium Cannabis Demand2301AN53.5% undervaluedAnalystHighTarget•1d agoExpanded Valleyfield Capacity And Blue River Partnership Will Anchor Long-Term Cannabis Upside000Top Analyst NarrativesAN38.0% undervaluedAnalystLowTarget•16d agoCapacity Expansion And Rising SG&A Will Test Margins Yet Future Exports May Offer Relief803AN41.6% undervaluedAnalystConsensusTarget•3mo agoExpanded Capacity And EU Export Optionality Will Support Long Term Premium Cannabis Demand2301AN53.5% undervaluedAnalystHighTarget•1d agoExpanded Valleyfield Capacity And Blue River Partnership Will Anchor Long-Term Cannabis Upside000View all narrativesCannara Biotech Inc. 경쟁사Jamieson WellnessSymbol: TSX:JWELMarket cap: CA$1.7bKP TissueSymbol: TSX:KPTMarket cap: CA$129.6mVytrus BiotechSymbol: BME:VYTMarket cap: €127.8mSacheeromeSymbol: NSEI:SACHEEROMEMarket cap: ₹9.5b가격 이력 및 성과Cannara Biotech 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$1.8652주 최고가CA$2.0752주 최저가CA$1.55베타0.351개월 변동5.68%3개월 변동4.49%1년 변동-1.06%3년 변동69.09%5년 변동9.41%IPO 이후 변동-39.02%최근 뉴스 및 업데이트새로운 내러티브 • Aug 01Expanded Valleyfield Capacity And Blue River Partnership Will Anchor Long-Term Cannabis UpsideCatalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products across Canada, supported by a vertically integrated cultivation and processing platform. What are the underlying business or industry changes driving this perspective?분석 기사 • Jul 23Earnings Troubles May Signal Larger Issues for Cannara Biotech (TSE:LOVE) ShareholdersThe subdued market reaction suggests that Cannara Biotech Inc.'s ( TSE:LOVE ) recent earnings didn't contain any...새로운 내러티브 • Jul 18Capacity Expansion And Rising SG&A Will Test Margins Yet Future Exports May Offer ReliefCatalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products in Canada through its Tribal, Nugz and Orchid brands, supported by vertically integrated cultivation and processing facilities. What are the underlying business or industry changes driving this perspective?Reported Earnings • Jul 17Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: CA$0.049 (up from CA$0.045 in 3Q 2025). Revenue: CA$31.8m (up 17% from 3Q 2025). Net income: CA$4.84m (up 17% from 3Q 2025). Profit margin: 15% (in line with 3Q 2025). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 29% per year.Price Target Changed • Jul 16Price target increased by 13% to CA$3.38Up from CA$3.00, the current price target is an average from 4 analysts. New target price is 76% above last closing price of CA$1.92. Stock is up 12% over the past year. The company is forecast to post earnings per share of CA$0.12 for next year compared to CA$0.14 last year.공고 • Jul 08Cannara Biotech Inc. to Report Q3, 2026 Results on Jul 15, 2026Cannara Biotech Inc. announced that they will report Q3, 2026 results at 8:00 AM, US Eastern Standard Time on Jul 15, 2026더 많은 업데이트 보기Recent updates새로운 내러티브 • Aug 01Expanded Valleyfield Capacity And Blue River Partnership Will Anchor Long-Term Cannabis UpsideCatalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products across Canada, supported by a vertically integrated cultivation and processing platform. What are the underlying business or industry changes driving this perspective?분석 기사 • Jul 23Earnings Troubles May Signal Larger Issues for Cannara Biotech (TSE:LOVE) ShareholdersThe subdued market reaction suggests that Cannara Biotech Inc.'s ( TSE:LOVE ) recent earnings didn't contain any...새로운 내러티브 • Jul 18Capacity Expansion And Rising SG&A Will Test Margins Yet Future Exports May Offer ReliefCatalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products in Canada through its Tribal, Nugz and Orchid brands, supported by vertically integrated cultivation and processing facilities. What are the underlying business or industry changes driving this perspective?Reported Earnings • Jul 17Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: CA$0.049 (up from CA$0.045 in 3Q 2025). Revenue: CA$31.8m (up 17% from 3Q 2025). Net income: CA$4.84m (up 17% from 3Q 2025). Profit margin: 15% (in line with 3Q 2025). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 29% per year.Price Target Changed • Jul 16Price target increased by 13% to CA$3.38Up from CA$3.00, the current price target is an average from 4 analysts. New target price is 76% above last closing price of CA$1.92. Stock is up 12% over the past year. The company is forecast to post earnings per share of CA$0.12 for next year compared to CA$0.14 last year.공고 • Jul 08Cannara Biotech Inc. to Report Q3, 2026 Results on Jul 15, 2026Cannara Biotech Inc. announced that they will report Q3, 2026 results at 8:00 AM, US Eastern Standard Time on Jul 15, 2026공고 • May 08+ 1 more updateCannara Announces Nicholas Sosiak as Interim CFO During TransitionCannara Biotech Inc. announced that Nicholas Sosiak has been appointed Chief Operating Officer, effective April 23, 2026. Nicholas Sosiak, who has served as the Company's Chief Financial Officer since 2020, will transition fully into his new operational role as Chief Operating Officer while Cannara conducts a search for his successor as CFO. The Company has initiated a search for a new Chief Financial Officer, including both internal and external candidates. Mr. Sosiak will continue to act as the Company’s interim CFO throughout the search and will work closely with his successor to ensure a seamless transition of CFO responsibilities.새로운 내러티브 • Apr 25Expanded Capacity And EU Export Optionality Will Support Long Term Premium Cannabis DemandCatalysts About Cannara Biotech Cannara Biotech is a vertically integrated Canadian cannabis producer focused on premium branded products at competitive price points. What are the underlying business or industry changes driving this perspective?Reported Earnings • Apr 15Second quarter 2026 earnings: EPS and revenues miss analyst expectationsSecond quarter 2026 results: EPS: CA$0.017 (down from CA$0.037 in 2Q 2025). Revenue: CA$27.2m (up 2.7% from 2Q 2025). Net income: CA$1.66m (down 50% from 2Q 2025). Profit margin: 6.1% (down from 13% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 50%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 33% per year whereas the company’s share price has increased by 29% per year.공고 • Apr 07Cannara Biotech Inc. to Report Q2, 2026 Results on Apr 14, 2026Cannara Biotech Inc. announced that they will report Q2, 2026 results at 7:00 AM, US Eastern Standard Time on Apr 14, 2026공고 • Feb 05Cannara Biotech Inc. announced that it has received CAD 6.3 million in funding from Phoenician Capital LLC and another investorCannara Biotech Inc. announced a non-brokered private placement of 3,000,000 common shares of the Company at a price of CAD 2.10 per Common Share for gross proceeds of CAD 6,300,000 on February 4, 2026. The transaction involves participation from new investor Phoenician Capital LLC. The issue price of the Common Shares represents an approximate 16% premium to the Company’s closing price on February 3, 2026, the last trading day prior to the announcement of the Private Placement. The Common Shares issued in connection with the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws and the policies of the TSXV. No finder’s fees or commissions were paid in connection with the Private Placement. The transaction is subject to final acceptance of the TSX Venture Exchange. The Company further announces that Zohar Krivorot has entered into an agreement to sell, on an exempt basis, 333,333 Common Shares of the Company to Phoenician at a price of CAD 2.10 per Common Share. The Company is not a party to the Secondary Share Sale and will not receive any proceeds from the transaction, which was undertaken solely to offset personal tax losses arising due to the recent vesting of certain restricted share units in the Company. The Common Shares sold to Phoenician under the Secondary Share sale are also subject to restrictions on transfer for a period of four months and one day. Prior to completion of the Secondary Share Sale, the individual investor beneficially owns or exercises control or direction over, directly or indirectly, 25,852,540 Common Shares of the Company, representing approximately 26.99% of the issued and outstanding Common Shares. Upon completion of the Secondary Share Sale, individual investor is expected to beneficially own or exercise control or direction over, directly or Cannara Biotech Inc 2 indirectly, 25,519,207 Common Shares of the Company, representing approximately 25.83% of the issued and outstanding Common Shares, after giving effect to the Private Placement.Reported Earnings • Jan 26First quarter 2026 earnings released: EPS: CA$0.011 (vs CA$0.026 in 1Q 2025)First quarter 2026 results: EPS: CA$0.011 (down from CA$0.026 in 1Q 2025). Revenue: CA$30.1m (up 21% from 1Q 2025). Net income: CA$1.04m (down 55% from 1Q 2025). Profit margin: 3.5% (down from 9.2% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.공고 • Jan 14Cannara Biotech Inc. to Report Q1, 2026 Results on Jan 26, 2026Cannara Biotech Inc. announced that they will report Q1, 2026 results at 7:00 AM, US Eastern Standard Time on Jan 26, 2026분석 기사 • Dec 01Cannara Biotech (CVE:LOVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfCannara Biotech Inc.'s ( CVE:LOVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...공고 • Nov 26Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026.Reported Earnings • Nov 25Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: CA$0.14 (up from CA$0.071 in FY 2024). Revenue: CA$107.3m (up 31% from FY 2024). Net income: CA$13.1m (up 103% from FY 2024). Profit margin: 12% (up from 7.9% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 40%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.공고 • Nov 18Cannara Biotech Inc. Announces the Passing of Jack M. Kay Member of the Board of DirectorCannara Biotech Inc. announced the passing of Jack M. Kay, a long-serving and highly respected member of the Board of Directors. Mr. Kay, who joined the Board in 2019, contributed more than five decades of leadership experience in pharmaceutical and sales executive management to the Corporation. Mr. Kay spent 35 years at Apotex Inc., where he held several senior executive positions, including Chief Executive Officer, Chief Operating Officer, President, and Vice Chairman. He also served in key leadership roles across the pharmaceutical and biotechnology sectors, including Chairman of Helix Biopharma Corp. and Cangene Corp., and Director of Barr Pharmaceuticals Inc. In addition to his industry contributions, Mr. Kay was a dedicated community leader, notably serving as Chairman of the Humber River Regional Hospital (Toronto) and as an executive member of several healthcare and industry organizations.공고 • Nov 17Cannara Biotech Inc. to Report Q4, 2025 Results on Nov 24, 2025Cannara Biotech Inc. announced that they will report Q4, 2025 results at 7:00 AM, US Eastern Standard Time on Nov 24, 2025Reported Earnings • Jul 29Third quarter 2025 earnings released: EPS: CA$0.045 (vs CA$0.022 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.045 (up from CA$0.022 in 3Q 2024). Revenue: CA$27.3m (up 40% from 3Q 2024). Net income: CA$4.14m (up 105% from 3Q 2024). Profit margin: 15% (up from 10% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.공고 • Jul 21Cannara Biotech Inc. to Report Q3, 2025 Results on Jul 28, 2025Cannara Biotech Inc. announced that they will report Q3, 2025 results at 7:00 AM, US Eastern Standard Time on Jul 28, 2025Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CA$1.67, the stock trades at a trailing P/E ratio of 11.4x. Average forward P/E is 22x in the Personal Products industry in North America. Total returns to shareholders of 52% over the past three years.분석 기사 • Jul 05Investors Still Aren't Entirely Convinced By Cannara Biotech Inc.'s (CVE:LOVE) Earnings Despite 27% Price JumpCannara Biotech Inc. ( CVE:LOVE ) shareholders have had their patience rewarded with a 27% share price jump in the last...분석 기사 • May 09A Piece Of The Puzzle Missing From Cannara Biotech Inc.'s (CVE:LOVE) 26% Share Price ClimbCannara Biotech Inc. ( CVE:LOVE ) shares have had a really impressive month, gaining 26% after a shaky period...분석 기사 • May 07There May Be Underlying Issues With The Quality Of Cannara Biotech's (CVE:LOVE) EarningsCannara Biotech Inc.'s ( CVE:LOVE ) robust earnings report didn't manage to move the market for its stock. We did some...공고 • Apr 16Cannara Biotech Inc. to Report Q2, 2025 Results on Apr 28, 2025Cannara Biotech Inc. announced that they will report Q2, 2025 results at 7:00 AM, US Eastern Standard Time on Apr 28, 2025Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CA$1.06, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 21x in the Personal Products industry in North America. Total loss to shareholders of 3.6% over the past three years.분석 기사 • Apr 07We Like These Underlying Return On Capital Trends At Cannara Biotech (CVE:LOVE)There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...공고 • Mar 24Cannara Biotech Inc. Announces Appointment of Justin Cohen to Board of DirectorsCannara Biotech Inc. announced the appointment of Mr. Justin Cohen to its board of directors as an independent director. Mr. Cohen will also serve as a member of the Audit Committee. Mr. Cohen is a seasoned executive with a track record of driving transformational growth and providing valuable leadership in brand development, sales and marketing. As Chief Marketing and Chief Commercial Officer at Psycho Bunny, he spearheaded the brand’s evolution from a niche player to a global powerhouse. Under his leadership, revenues increased tenfold over three years, driven by strategic retail expansion, digital acceleration, and brand reinvention. Prior to Psycho Bunny, Mr. Cohen led direct-to-consumer and e-commerce strategy at Keurig Dr Pepper, expanding its digital footprint and scaling revenue across online and omnichannel platforms. He has also held leadership roles at Google, ALDO Group, and Sony Music, where he guided brands through digital transformation and new growth opportunities. Currently, as a senior executive at Cosmetic Physician Partners, Mr. Cohen oversees integrated marketing across a portfolio of over 55 clinics in the United States, ensuring scalable and sustainable expansion. In addition to his corporate leadership, he serves on the board of Dose Juice, advising on commercial strategy, market expansion, and operational efficiency. Mr. Cohen holds degrees in Marketing & Advertising, an MBA, and a master’s in behavioral science from the London School of Economics.Valuation Update With 7 Day Price Move • Feb 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.25, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 27x in the Personal Products industry in North America. Total loss to shareholders of 3.8% over the past three years.분석 기사 • Jan 29A Piece Of The Puzzle Missing From Cannara Biotech Inc.'s (CVE:LOVE) 40% Share Price ClimbCannara Biotech Inc. ( CVE:LOVE ) shareholders have had their patience rewarded with a 40% share price jump in the last...Reported Earnings • Jan 27First quarter 2025 earnings released: EPS: CA$0.026 (vs CA$0.023 in 1Q 2024)First quarter 2025 results: EPS: CA$0.026 (up from CA$0.023 in 1Q 2024). Revenue: CA$25.1m (up 29% from 1Q 2024). Net income: CA$2.31m (up 9.4% from 1Q 2024). Profit margin: 9.2% (down from 11% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.분석 기사 • Jan 03Returns At Cannara Biotech (CVE:LOVE) Are On The Way UpIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...분석 기사 • Nov 26Benign Growth For Cannara Biotech Inc. (CVE:LOVE) Underpins Its Share PriceWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") above 15x, you may consider...공고 • Nov 26Cannara Biotech Inc. Plans to Launch over 20 New Products in High Volume CategoriesCannara Biotech Inc. announced for fiscal 2025, the company plans to launch over 20 new products in high volume categories, including innovative formats like all-in-one vape devices under Tribal and Nugz, and premium infused pre-rolls under Tribal. A rigorous pheno-hunting program underpins these developments, unlocking unique genetics tailored to brand fit, potency, structure, and market appeal. In April 2024, Cannara introduced three new genetics: Neon Sunshine and Bubble Up (Tribal) and Guava Jam (Nugz).Reported Earnings • Nov 26Full year 2024 earnings released: EPS: CA$0.071 (vs CA$0.078 in FY 2023)Full year 2024 results: EPS: CA$0.071 (down from CA$0.078 in FY 2023). Revenue: CA$82.1m (up 44% from FY 2023). Net income: CA$6.44m (down 7.3% from FY 2023). Profit margin: 7.8% (down from 12% in FY 2023). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.공고 • Nov 12Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025.분석 기사 • Oct 29These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt ExtensivelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Sep 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.8x net interest cover). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (CA$59.4m market cap, or US$44.1m).분석 기사 • Aug 22Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With EarningsThose holding Cannara Biotech Inc. ( CVE:LOVE ) shares would be relieved that the share price has rebounded 33% in the...분석 기사 • Aug 21Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To ContinueIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Reported Earnings • Jul 24Third quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.033 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.022 (down from CA$0.033 in 3Q 2023). Revenue: CA$19.5m (up 23% from 3Q 2023). Net income: CA$2.02m (down 31% from 3Q 2023). Profit margin: 10% (down from 18% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.분석 기사 • Jul 14Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • May 09Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift SharesCannara Biotech Inc.'s ( CVE:LOVE ) price-to-earnings (or "P/E") ratio of 10.7x might make it look like a buy right now...Reported Earnings • Apr 30Second quarter 2024 earnings released: CA$0.038 loss per share (vs CA$0.007 loss in 2Q 2023)Second quarter 2024 results: CA$0.038 loss per share (further deteriorated from CA$0.007 loss in 2Q 2023). Revenue: CA$19.7m (up 51% from 2Q 2023). Net loss: CA$3.45m (loss widened 458% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.분석 기사 • Feb 28Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention TodayIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Reported Earnings • Jan 30First quarter 2024 earnings released: EPS: CA$0.023 (vs CA$0 in 1Q 2023)First quarter 2024 results: EPS: CA$0.023 (up from CA$0 in 1Q 2023). Revenue: CA$19.5m (up 89% from 1Q 2023). Net income: CA$2.11m (up CA$2.10m from 1Q 2023). Profit margin: 11% (up from 0% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.분석 기사 • Jan 24Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is LackingIt's not a stretch to say that Cannara Biotech Inc.'s ( CVE:LOVE ) price-to-earnings (or "P/E") ratio of 11.8x right...분석 기사 • Dec 18Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting PointCannara Biotech Inc.'s ( CVE:LOVE ) stock was strong after they recently reported robust earnings. We did some analysis...Reported Earnings • Dec 08Full year 2023 earnings released: EPS: CA$0.078 (vs CA$0.026 in FY 2022)Full year 2023 results: EPS: CA$0.078 (up from CA$0.026 in FY 2022). Revenue: CA$57.6m (up 61% from FY 2022). Net income: CA$6.95m (up 201% from FY 2022). Profit margin: 12% (up from 6.4% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 126% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Lead Director Don Olds was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Nov 13Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024.분석 기사 • Jul 29Is Cannara Biotech (CVE:LOVE) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Reported Earnings • Jul 28Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.016 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.03 (up from CA$0.016 in 3Q 2022). Revenue: CA$15.9m (up 58% from 3Q 2022). Net income: CA$2.93m (up 105% from 3Q 2022). Profit margin: 18% (up from 14% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Recent Insider Transactions • Jun 04Independent Director recently bought CA$60k worth of stockOn the 31st of May, Derek Stern bought around 53k shares on-market at roughly CA$1.13 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$530k more in shares than they have sold in the last 12 months.Valuation Update With 7 Day Price Move • May 31Investor sentiment improves as stock rises 24%After last week's 24% share price gain to CA$1.05, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 10x in the Pharmaceuticals industry in Canada. Negligible returns to shareholders over past three years.Reported Earnings • Apr 26Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 2Q 2022)Second quarter 2023 results: CA$0.007 loss per share (improved from CA$0.013 loss in 2Q 2022). Revenue: CA$13.0m (up 76% from 2Q 2022). Net loss: CA$618.1k (loss narrowed 46% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.분석 기사 • Apr 10Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share PriceWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") below 10x, you may consider...분석 기사 • Jan 26Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt BurdenDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Jan 24First quarter 2023 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2022). Revenue: CA$10.3m (up 57% from 1Q 2022). Net income: CA$3.0k (up CA$533.5k from 1Q 2022). Profit margin: 0% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.공고 • Dec 03Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023.Recent Insider Transactions • Dec 02Independent Director recently bought CA$117k worth of stockOn the 30th of November, Derek Stern bought around 1m shares on-market at roughly CA$0.12 per share. This transaction amounted to 9.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$349k more in shares than they have sold in the last 12 months.Reported Earnings • Nov 25Full year 2022 earnings released: EPS: CA$0.003 (vs CA$0.002 loss in FY 2021)Full year 2022 results: EPS: CA$0.003 (up from CA$0.002 loss in FY 2021). Revenue: CA$36.0m (up 112% from FY 2021). Net income: CA$2.31m (up CA$3.83m from FY 2021). Profit margin: 6.4% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.공고 • Sep 21Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro ArkCannara Biotech Inc. announced its entry into the British Columbia (BC) market. In addition, the Company is also pleased to announce the launch of its first two premium product offerings in the vape and accessory categories. The Company has also introduced a premium universal 510 vape battery, the Tribal UNI Pro ARK, in collaboration with well-known premium vape manufacturer, Yocan, to provide a superior consumer vaping experience. "Cannara is pleased to have partnered with Yocan to deliver a vape battery that have the utmost confidence in.Recent Insider Transactions • Sep 09Independent Director recently bought CA$81k worth of stockOn the 31st of August, Derek Stern bought around 720k shares on-market at roughly CA$0.11 per share. This transaction amounted to 7.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$232k more in shares than they have sold in the last 12 months.Reported Earnings • Jul 28Third quarter 2022 earnings released: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021)Third quarter 2022 results: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021). Revenue: CA$10.1m (up 41% from 3Q 2021). Net income: CA$1.43m (down 16% from 3Q 2021). Profit margin: 14% (down from 24% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 28Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)Second quarter 2022 results: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021). Revenue: CA$7.42m (up 229% from 2Q 2021). Net loss: CA$1.15m (loss widened 33% from 2Q 2021).분석 기사 • Jan 27Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They AppearEven though Cannara Biotech Inc. ( CVE:LOVE ) posted strong earnings recently, the stock hasn't reacted in a large way...Reported Earnings • Jan 23First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.001 loss per share (up from CA$0.005 loss in 1Q 2021). Revenue: CA$6.56m (up 380% from 1Q 2021). Net loss: CA$530.5k (loss narrowed 85% from 1Q 2021). Revenue was in line with analyst estimates.공고 • Dec 10Cannara Biotech Inc. Announces New Products LaunchCannara Biotech Inc. Launched two new hash products within the Nugz brand in Quebec retail stores and Old School Hash in a 3-gram bar and Ice Water Hash in a 1-gram temple ball.분석 기사 • Dec 10Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Dec 10Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.002 loss per share (up from CA$0.017 loss in FY 2020). Revenue: CA$17.3m (up CA$14.7m from FY 2020). Net loss: CA$1.53m (loss narrowed 88% from FY 2020). Revenue was in line with analyst estimates.Board Change • Dec 06High number of new directorsIndependent Lead Director Don Olds was the last director to join the board, commencing their role in 2020.공고 • Sep 29Cannara Biotech Inc. Receives Processing and Cultivation LicenseCannara Biotech Inc. announced that it has received the license for cultivation and processing at its one million square foot cultivation and manufacturing facility in Valleyfield, Quebec. The majority of zones in the recently acquired greenhouse are being repurposed as an indoor facility to achieve the same growing conditions as Cannara's Farnham Facility, home of Tribal, Orchid CBD and Nugz. In the Company's first quarter in market, product sales surpassed $7 million with supply capabilities as the limiting factor. This ready build facility will allow the company to fasttrack time to market and will significantly increase product supply bolstering the company's revenues and footprint into new markets.공고 • Sep 03Cannara Biotech Inc. Receives Amendment of Its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of Its Hash Product Line in QuebecCannara Biotech Inc. announced it has received an amendment of its License from Health Canada, permitting the sale of Cannabis 2.0 products for which the Company intends to use to commercialize hash and other solventless concentrates, solvent-based concentrates, vaporizers, tinctures and topicals. Cannara is excited to announce the first expansion of its Nugz product line: OId School Hash and Ice Water Hash. These two products will first be launched in Quebec and have been specifically formulated for the Quebec market to provide quality hash that contains less than 30% THC. Both products are expected to be available to consumers in the Fall and will be offered in rotating genetics to provide a choice of flavours, terpenes and cannabinoid concentrations from the company's library of rare strains. Nugz Old School Hash is a traditional hash produced using age-old sieving methods and drawn from rare cannabis strains, dry-sifted, gently heated, and pressed into a consistent, sticky, malleable resin. Old School Hash will be available in three-gram bars. Nugz Ice Water Hash is a bubble hash derived from carefully selected single-source THC and CBD indoor-grown whole bud, extracted through ice water to deliver true-to-strain terpene profiles. Ice Water Hash will be available in one gram temple balls. Cannara reaches new Canadians through expansion to Ontario and Saskatchewan. Building on its success in the Quebec market, Cannara has expanded to Ontario and Saskatchewan, extending its reach to a new segment of consumers and marking a significant milestone in the Company's mission to become a leading Canadian cannabis producer. Dried flower and pre-roll products from Cannara's existing Tribal and Nugz lines are currently available at cannabis retailers across Saskatchewan, with the existing Tribal, Orchid CBD and Nugz product lines expected to launch in Ontario starting mid-September 2021.Reported Earnings • Jul 30Third quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.003 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$7.16m (up CA$6.40m from 3Q 2020). Net income: CA$1.70m (up CA$4.07m from 3Q 2020). Profit margin: 24% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.공고 • Jun 25+ 1 more updateCannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc.Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million on June 10, 2021. Pursuant to the agreement, Cannara Biotech will have deposited the full CAD 27 million into escrow prior to the close of the sale. Additional CAD 5.7 million deposit to be refunded to Medican upon completion of the transfer to Cannara of a utility pricing agreement with Hydro Quebec, to occur concurrently with Closing. The acquisition will be financed by a non-brokered private placement of up to CAD 35,000,000. The acquisition was financed through non-brokered private placements of CAD 19.3 million resulting in the issuance of 107,222,222 new common shares in the capital of Cannara at a price of $0.18 per share and CAD 5.7 million in the form of an unsecured convertible debenture bearing interest at 4% per annum. The sole subscriber to the Offerings is Olymbec Investments Inc. The transaction closing is subject to usual and customary conditions. Sale expected to close on or before June 22, 2021. The Green will use net proceeds to eliminate senior term debt. BMO Capital Markets acted as financial advisor and Langlois Lawyers LLP acted as legal counsel for The Green Organic Dutchman Holdings Ltd., parent of Medican Organic Inc. Cannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc. on June 23, 2021.공고 • Jun 11Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million.Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million on June 10, 2021. Pursuant to the agreement, Cannara Biotech will have deposited the full CAD 27 million (the “Purchase Price”) into escrow prior to the close of the sale. Additional CAD 5.7 million deposit to be refunded to Medican upon completion of the transfer to Cannara of a utility pricing agreement with Hydro Quebec, to occur concurrently with Closing. The acquisition will be financed by a non-brokered private placement of up to CAD 35,000,000. The transaction closing is subject to usual and customary conditions. Sale expected to close on or before June 22, 2021. The Green will use net proceeds to eliminate senior term debt. BMO Capital Markets acted as financial advisor and Langlois Lawyers LLP acted as legal counsel for The Green Organic Dutchman Holdings Ltd., parent of Medican Organic Inc.분석 기사 • Mar 16Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Feb 01First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.004 loss in 1Q 2020)First quarter 2021 results: Net loss: CA$3.50m (loss widened 28% from 1Q 2020).분석 기사 • Jan 22Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?Cannara Biotech Inc. ( CSE:LOVE ) shareholders will doubtless be very grateful to see the share price up 81% in the...분석 기사 • Dec 18Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...Reported Earnings • Dec 17Full year 2020 earnings released: CA$0.017 loss per shareFull year 2020 results: Net loss: CA$12.5m (loss widened 1.4% from FY 2019).공고 • Nov 14Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021.공고 • Nov 06Cannara Biotech Inc. Appoints Donald Olds to Board of DirectorsCannara Biotech Inc. announced the appointment of Donald Olds as a Director on the Company's board of directors. Donald Olds is an experienced life sciences executive, entrepreneur and director with significant experience raising capital for private and public technology companies. Most recently, he was President and Chief Executive Officer of Montreal-based NEOMED Institute.주주 수익률LOVECA Personal ProductsCA 시장7D-2.1%1.1%-0.4%1Y-1.1%18.2%30.2%전체 주주 수익률 보기수익률 대 산업: LOVE은 지난 1년 동안 18.2%의 수익을 기록한 Canadian Personal Products 산업보다 저조한 성과를 냈습니다.수익률 대 시장: LOVE은 지난 1년 동안 30.2%를 기록한 Canadian 시장보다 저조한 성과를 냈습니다.주가 변동성Is LOVE's price volatile compared to industry and market?LOVE volatilityLOVE Average Weekly Movement4.6%Personal Products Industry Average Movement8.2%Market Average Movement9.4%10% most volatile stocks in CA Market16.3%10% least volatile stocks in CA Market3.7%안정적인 주가: LOVE는 지난 3개월 동안 Canadian 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: LOVE의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트2017452Zohar Krivorotcannara.ca는 자회사와 함께 캐나다에서 대마초 및 대마초 유래 제품의 실내 재배, 가공 및 판매에 종사하고 있습니다. 이 회사는 도매업체와 온라인 판매업체를 통해 제품을 판매합니다. 또한 부동산 운영에도 관여하고 있습니다.더 보기Cannara Biotech Inc. 기초 지표 요약Cannara Biotech의 순이익과 매출은 시가총액과 어떻게 비교됩니까?LOVE 기초 통계시가총액CA$185.71m순이익 (TTM)CA$10.86m매출 (TTM)CA$117.33m16.9x주가수익비율(P/E)1.6x주가매출비율(P/S)LOVE는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표LOVE 손익계산서 (TTM)매출CA$117.33m매출원가CA$67.36m총이익CA$49.97m기타 비용CA$39.12m순이익CA$10.86m최근 보고된 실적May 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)0.11총이익률42.59%순이익률9.25%부채/자본 비율29.3%LOVE의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/31 12:56종가2026/07/31 00:00수익2026/05/31연간 수익2025/08/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cannara Biotech Inc.는 4명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Nicholas CortellucciAtrium ResearchNeal GilmerHaywood Securities Inc.Greg McLeishResearch Capital Corporation1명의 분석가 더 보기
새로운 내러티브 • Aug 01Expanded Valleyfield Capacity And Blue River Partnership Will Anchor Long-Term Cannabis UpsideCatalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products across Canada, supported by a vertically integrated cultivation and processing platform. What are the underlying business or industry changes driving this perspective?
분석 기사 • Jul 23Earnings Troubles May Signal Larger Issues for Cannara Biotech (TSE:LOVE) ShareholdersThe subdued market reaction suggests that Cannara Biotech Inc.'s ( TSE:LOVE ) recent earnings didn't contain any...
새로운 내러티브 • Jul 18Capacity Expansion And Rising SG&A Will Test Margins Yet Future Exports May Offer ReliefCatalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products in Canada through its Tribal, Nugz and Orchid brands, supported by vertically integrated cultivation and processing facilities. What are the underlying business or industry changes driving this perspective?
Reported Earnings • Jul 17Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: CA$0.049 (up from CA$0.045 in 3Q 2025). Revenue: CA$31.8m (up 17% from 3Q 2025). Net income: CA$4.84m (up 17% from 3Q 2025). Profit margin: 15% (in line with 3Q 2025). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 29% per year.
Price Target Changed • Jul 16Price target increased by 13% to CA$3.38Up from CA$3.00, the current price target is an average from 4 analysts. New target price is 76% above last closing price of CA$1.92. Stock is up 12% over the past year. The company is forecast to post earnings per share of CA$0.12 for next year compared to CA$0.14 last year.
공고 • Jul 08Cannara Biotech Inc. to Report Q3, 2026 Results on Jul 15, 2026Cannara Biotech Inc. announced that they will report Q3, 2026 results at 8:00 AM, US Eastern Standard Time on Jul 15, 2026
새로운 내러티브 • Aug 01Expanded Valleyfield Capacity And Blue River Partnership Will Anchor Long-Term Cannabis UpsideCatalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products across Canada, supported by a vertically integrated cultivation and processing platform. What are the underlying business or industry changes driving this perspective?
분석 기사 • Jul 23Earnings Troubles May Signal Larger Issues for Cannara Biotech (TSE:LOVE) ShareholdersThe subdued market reaction suggests that Cannara Biotech Inc.'s ( TSE:LOVE ) recent earnings didn't contain any...
새로운 내러티브 • Jul 18Capacity Expansion And Rising SG&A Will Test Margins Yet Future Exports May Offer ReliefCatalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products in Canada through its Tribal, Nugz and Orchid brands, supported by vertically integrated cultivation and processing facilities. What are the underlying business or industry changes driving this perspective?
Reported Earnings • Jul 17Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: CA$0.049 (up from CA$0.045 in 3Q 2025). Revenue: CA$31.8m (up 17% from 3Q 2025). Net income: CA$4.84m (up 17% from 3Q 2025). Profit margin: 15% (in line with 3Q 2025). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 29% per year.
Price Target Changed • Jul 16Price target increased by 13% to CA$3.38Up from CA$3.00, the current price target is an average from 4 analysts. New target price is 76% above last closing price of CA$1.92. Stock is up 12% over the past year. The company is forecast to post earnings per share of CA$0.12 for next year compared to CA$0.14 last year.
공고 • Jul 08Cannara Biotech Inc. to Report Q3, 2026 Results on Jul 15, 2026Cannara Biotech Inc. announced that they will report Q3, 2026 results at 8:00 AM, US Eastern Standard Time on Jul 15, 2026
공고 • May 08+ 1 more updateCannara Announces Nicholas Sosiak as Interim CFO During TransitionCannara Biotech Inc. announced that Nicholas Sosiak has been appointed Chief Operating Officer, effective April 23, 2026. Nicholas Sosiak, who has served as the Company's Chief Financial Officer since 2020, will transition fully into his new operational role as Chief Operating Officer while Cannara conducts a search for his successor as CFO. The Company has initiated a search for a new Chief Financial Officer, including both internal and external candidates. Mr. Sosiak will continue to act as the Company’s interim CFO throughout the search and will work closely with his successor to ensure a seamless transition of CFO responsibilities.
새로운 내러티브 • Apr 25Expanded Capacity And EU Export Optionality Will Support Long Term Premium Cannabis DemandCatalysts About Cannara Biotech Cannara Biotech is a vertically integrated Canadian cannabis producer focused on premium branded products at competitive price points. What are the underlying business or industry changes driving this perspective?
Reported Earnings • Apr 15Second quarter 2026 earnings: EPS and revenues miss analyst expectationsSecond quarter 2026 results: EPS: CA$0.017 (down from CA$0.037 in 2Q 2025). Revenue: CA$27.2m (up 2.7% from 2Q 2025). Net income: CA$1.66m (down 50% from 2Q 2025). Profit margin: 6.1% (down from 13% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 50%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 33% per year whereas the company’s share price has increased by 29% per year.
공고 • Apr 07Cannara Biotech Inc. to Report Q2, 2026 Results on Apr 14, 2026Cannara Biotech Inc. announced that they will report Q2, 2026 results at 7:00 AM, US Eastern Standard Time on Apr 14, 2026
공고 • Feb 05Cannara Biotech Inc. announced that it has received CAD 6.3 million in funding from Phoenician Capital LLC and another investorCannara Biotech Inc. announced a non-brokered private placement of 3,000,000 common shares of the Company at a price of CAD 2.10 per Common Share for gross proceeds of CAD 6,300,000 on February 4, 2026. The transaction involves participation from new investor Phoenician Capital LLC. The issue price of the Common Shares represents an approximate 16% premium to the Company’s closing price on February 3, 2026, the last trading day prior to the announcement of the Private Placement. The Common Shares issued in connection with the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws and the policies of the TSXV. No finder’s fees or commissions were paid in connection with the Private Placement. The transaction is subject to final acceptance of the TSX Venture Exchange. The Company further announces that Zohar Krivorot has entered into an agreement to sell, on an exempt basis, 333,333 Common Shares of the Company to Phoenician at a price of CAD 2.10 per Common Share. The Company is not a party to the Secondary Share Sale and will not receive any proceeds from the transaction, which was undertaken solely to offset personal tax losses arising due to the recent vesting of certain restricted share units in the Company. The Common Shares sold to Phoenician under the Secondary Share sale are also subject to restrictions on transfer for a period of four months and one day. Prior to completion of the Secondary Share Sale, the individual investor beneficially owns or exercises control or direction over, directly or indirectly, 25,852,540 Common Shares of the Company, representing approximately 26.99% of the issued and outstanding Common Shares. Upon completion of the Secondary Share Sale, individual investor is expected to beneficially own or exercise control or direction over, directly or Cannara Biotech Inc 2 indirectly, 25,519,207 Common Shares of the Company, representing approximately 25.83% of the issued and outstanding Common Shares, after giving effect to the Private Placement.
Reported Earnings • Jan 26First quarter 2026 earnings released: EPS: CA$0.011 (vs CA$0.026 in 1Q 2025)First quarter 2026 results: EPS: CA$0.011 (down from CA$0.026 in 1Q 2025). Revenue: CA$30.1m (up 21% from 1Q 2025). Net income: CA$1.04m (down 55% from 1Q 2025). Profit margin: 3.5% (down from 9.2% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
공고 • Jan 14Cannara Biotech Inc. to Report Q1, 2026 Results on Jan 26, 2026Cannara Biotech Inc. announced that they will report Q1, 2026 results at 7:00 AM, US Eastern Standard Time on Jan 26, 2026
분석 기사 • Dec 01Cannara Biotech (CVE:LOVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfCannara Biotech Inc.'s ( CVE:LOVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...
공고 • Nov 26Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026.
Reported Earnings • Nov 25Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: CA$0.14 (up from CA$0.071 in FY 2024). Revenue: CA$107.3m (up 31% from FY 2024). Net income: CA$13.1m (up 103% from FY 2024). Profit margin: 12% (up from 7.9% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 40%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
공고 • Nov 18Cannara Biotech Inc. Announces the Passing of Jack M. Kay Member of the Board of DirectorCannara Biotech Inc. announced the passing of Jack M. Kay, a long-serving and highly respected member of the Board of Directors. Mr. Kay, who joined the Board in 2019, contributed more than five decades of leadership experience in pharmaceutical and sales executive management to the Corporation. Mr. Kay spent 35 years at Apotex Inc., where he held several senior executive positions, including Chief Executive Officer, Chief Operating Officer, President, and Vice Chairman. He also served in key leadership roles across the pharmaceutical and biotechnology sectors, including Chairman of Helix Biopharma Corp. and Cangene Corp., and Director of Barr Pharmaceuticals Inc. In addition to his industry contributions, Mr. Kay was a dedicated community leader, notably serving as Chairman of the Humber River Regional Hospital (Toronto) and as an executive member of several healthcare and industry organizations.
공고 • Nov 17Cannara Biotech Inc. to Report Q4, 2025 Results on Nov 24, 2025Cannara Biotech Inc. announced that they will report Q4, 2025 results at 7:00 AM, US Eastern Standard Time on Nov 24, 2025
Reported Earnings • Jul 29Third quarter 2025 earnings released: EPS: CA$0.045 (vs CA$0.022 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.045 (up from CA$0.022 in 3Q 2024). Revenue: CA$27.3m (up 40% from 3Q 2024). Net income: CA$4.14m (up 105% from 3Q 2024). Profit margin: 15% (up from 10% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in North America. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
공고 • Jul 21Cannara Biotech Inc. to Report Q3, 2025 Results on Jul 28, 2025Cannara Biotech Inc. announced that they will report Q3, 2025 results at 7:00 AM, US Eastern Standard Time on Jul 28, 2025
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CA$1.67, the stock trades at a trailing P/E ratio of 11.4x. Average forward P/E is 22x in the Personal Products industry in North America. Total returns to shareholders of 52% over the past three years.
분석 기사 • Jul 05Investors Still Aren't Entirely Convinced By Cannara Biotech Inc.'s (CVE:LOVE) Earnings Despite 27% Price JumpCannara Biotech Inc. ( CVE:LOVE ) shareholders have had their patience rewarded with a 27% share price jump in the last...
분석 기사 • May 09A Piece Of The Puzzle Missing From Cannara Biotech Inc.'s (CVE:LOVE) 26% Share Price ClimbCannara Biotech Inc. ( CVE:LOVE ) shares have had a really impressive month, gaining 26% after a shaky period...
분석 기사 • May 07There May Be Underlying Issues With The Quality Of Cannara Biotech's (CVE:LOVE) EarningsCannara Biotech Inc.'s ( CVE:LOVE ) robust earnings report didn't manage to move the market for its stock. We did some...
공고 • Apr 16Cannara Biotech Inc. to Report Q2, 2025 Results on Apr 28, 2025Cannara Biotech Inc. announced that they will report Q2, 2025 results at 7:00 AM, US Eastern Standard Time on Apr 28, 2025
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CA$1.06, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 21x in the Personal Products industry in North America. Total loss to shareholders of 3.6% over the past three years.
분석 기사 • Apr 07We Like These Underlying Return On Capital Trends At Cannara Biotech (CVE:LOVE)There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...
공고 • Mar 24Cannara Biotech Inc. Announces Appointment of Justin Cohen to Board of DirectorsCannara Biotech Inc. announced the appointment of Mr. Justin Cohen to its board of directors as an independent director. Mr. Cohen will also serve as a member of the Audit Committee. Mr. Cohen is a seasoned executive with a track record of driving transformational growth and providing valuable leadership in brand development, sales and marketing. As Chief Marketing and Chief Commercial Officer at Psycho Bunny, he spearheaded the brand’s evolution from a niche player to a global powerhouse. Under his leadership, revenues increased tenfold over three years, driven by strategic retail expansion, digital acceleration, and brand reinvention. Prior to Psycho Bunny, Mr. Cohen led direct-to-consumer and e-commerce strategy at Keurig Dr Pepper, expanding its digital footprint and scaling revenue across online and omnichannel platforms. He has also held leadership roles at Google, ALDO Group, and Sony Music, where he guided brands through digital transformation and new growth opportunities. Currently, as a senior executive at Cosmetic Physician Partners, Mr. Cohen oversees integrated marketing across a portfolio of over 55 clinics in the United States, ensuring scalable and sustainable expansion. In addition to his corporate leadership, he serves on the board of Dose Juice, advising on commercial strategy, market expansion, and operational efficiency. Mr. Cohen holds degrees in Marketing & Advertising, an MBA, and a master’s in behavioral science from the London School of Economics.
Valuation Update With 7 Day Price Move • Feb 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.25, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 27x in the Personal Products industry in North America. Total loss to shareholders of 3.8% over the past three years.
분석 기사 • Jan 29A Piece Of The Puzzle Missing From Cannara Biotech Inc.'s (CVE:LOVE) 40% Share Price ClimbCannara Biotech Inc. ( CVE:LOVE ) shareholders have had their patience rewarded with a 40% share price jump in the last...
Reported Earnings • Jan 27First quarter 2025 earnings released: EPS: CA$0.026 (vs CA$0.023 in 1Q 2024)First quarter 2025 results: EPS: CA$0.026 (up from CA$0.023 in 1Q 2024). Revenue: CA$25.1m (up 29% from 1Q 2024). Net income: CA$2.31m (up 9.4% from 1Q 2024). Profit margin: 9.2% (down from 11% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
분석 기사 • Jan 03Returns At Cannara Biotech (CVE:LOVE) Are On The Way UpIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
분석 기사 • Nov 26Benign Growth For Cannara Biotech Inc. (CVE:LOVE) Underpins Its Share PriceWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") above 15x, you may consider...
공고 • Nov 26Cannara Biotech Inc. Plans to Launch over 20 New Products in High Volume CategoriesCannara Biotech Inc. announced for fiscal 2025, the company plans to launch over 20 new products in high volume categories, including innovative formats like all-in-one vape devices under Tribal and Nugz, and premium infused pre-rolls under Tribal. A rigorous pheno-hunting program underpins these developments, unlocking unique genetics tailored to brand fit, potency, structure, and market appeal. In April 2024, Cannara introduced three new genetics: Neon Sunshine and Bubble Up (Tribal) and Guava Jam (Nugz).
Reported Earnings • Nov 26Full year 2024 earnings released: EPS: CA$0.071 (vs CA$0.078 in FY 2023)Full year 2024 results: EPS: CA$0.071 (down from CA$0.078 in FY 2023). Revenue: CA$82.1m (up 44% from FY 2023). Net income: CA$6.44m (down 7.3% from FY 2023). Profit margin: 7.8% (down from 12% in FY 2023). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
공고 • Nov 12Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025.
분석 기사 • Oct 29These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt ExtensivelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Sep 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.8x net interest cover). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (CA$59.4m market cap, or US$44.1m).
분석 기사 • Aug 22Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With EarningsThose holding Cannara Biotech Inc. ( CVE:LOVE ) shares would be relieved that the share price has rebounded 33% in the...
분석 기사 • Aug 21Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To ContinueIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
Reported Earnings • Jul 24Third quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.033 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.022 (down from CA$0.033 in 3Q 2023). Revenue: CA$19.5m (up 23% from 3Q 2023). Net income: CA$2.02m (down 31% from 3Q 2023). Profit margin: 10% (down from 18% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
분석 기사 • Jul 14Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • May 09Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift SharesCannara Biotech Inc.'s ( CVE:LOVE ) price-to-earnings (or "P/E") ratio of 10.7x might make it look like a buy right now...
Reported Earnings • Apr 30Second quarter 2024 earnings released: CA$0.038 loss per share (vs CA$0.007 loss in 2Q 2023)Second quarter 2024 results: CA$0.038 loss per share (further deteriorated from CA$0.007 loss in 2Q 2023). Revenue: CA$19.7m (up 51% from 2Q 2023). Net loss: CA$3.45m (loss widened 458% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
분석 기사 • Feb 28Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention TodayIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Reported Earnings • Jan 30First quarter 2024 earnings released: EPS: CA$0.023 (vs CA$0 in 1Q 2023)First quarter 2024 results: EPS: CA$0.023 (up from CA$0 in 1Q 2023). Revenue: CA$19.5m (up 89% from 1Q 2023). Net income: CA$2.11m (up CA$2.10m from 1Q 2023). Profit margin: 11% (up from 0% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
분석 기사 • Jan 24Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is LackingIt's not a stretch to say that Cannara Biotech Inc.'s ( CVE:LOVE ) price-to-earnings (or "P/E") ratio of 11.8x right...
분석 기사 • Dec 18Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting PointCannara Biotech Inc.'s ( CVE:LOVE ) stock was strong after they recently reported robust earnings. We did some analysis...
Reported Earnings • Dec 08Full year 2023 earnings released: EPS: CA$0.078 (vs CA$0.026 in FY 2022)Full year 2023 results: EPS: CA$0.078 (up from CA$0.026 in FY 2022). Revenue: CA$57.6m (up 61% from FY 2022). Net income: CA$6.95m (up 201% from FY 2022). Profit margin: 12% (up from 6.4% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 126% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Lead Director Don Olds was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Nov 13Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024.
분석 기사 • Jul 29Is Cannara Biotech (CVE:LOVE) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Reported Earnings • Jul 28Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.016 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.03 (up from CA$0.016 in 3Q 2022). Revenue: CA$15.9m (up 58% from 3Q 2022). Net income: CA$2.93m (up 105% from 3Q 2022). Profit margin: 18% (up from 14% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Recent Insider Transactions • Jun 04Independent Director recently bought CA$60k worth of stockOn the 31st of May, Derek Stern bought around 53k shares on-market at roughly CA$1.13 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$530k more in shares than they have sold in the last 12 months.
Valuation Update With 7 Day Price Move • May 31Investor sentiment improves as stock rises 24%After last week's 24% share price gain to CA$1.05, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 10x in the Pharmaceuticals industry in Canada. Negligible returns to shareholders over past three years.
Reported Earnings • Apr 26Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 2Q 2022)Second quarter 2023 results: CA$0.007 loss per share (improved from CA$0.013 loss in 2Q 2022). Revenue: CA$13.0m (up 76% from 2Q 2022). Net loss: CA$618.1k (loss narrowed 46% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 10Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share PriceWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") below 10x, you may consider...
분석 기사 • Jan 26Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt BurdenDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Jan 24First quarter 2023 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2022). Revenue: CA$10.3m (up 57% from 1Q 2022). Net income: CA$3.0k (up CA$533.5k from 1Q 2022). Profit margin: 0% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
공고 • Dec 03Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023.
Recent Insider Transactions • Dec 02Independent Director recently bought CA$117k worth of stockOn the 30th of November, Derek Stern bought around 1m shares on-market at roughly CA$0.12 per share. This transaction amounted to 9.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$349k more in shares than they have sold in the last 12 months.
Reported Earnings • Nov 25Full year 2022 earnings released: EPS: CA$0.003 (vs CA$0.002 loss in FY 2021)Full year 2022 results: EPS: CA$0.003 (up from CA$0.002 loss in FY 2021). Revenue: CA$36.0m (up 112% from FY 2021). Net income: CA$2.31m (up CA$3.83m from FY 2021). Profit margin: 6.4% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
공고 • Sep 21Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro ArkCannara Biotech Inc. announced its entry into the British Columbia (BC) market. In addition, the Company is also pleased to announce the launch of its first two premium product offerings in the vape and accessory categories. The Company has also introduced a premium universal 510 vape battery, the Tribal UNI Pro ARK, in collaboration with well-known premium vape manufacturer, Yocan, to provide a superior consumer vaping experience. "Cannara is pleased to have partnered with Yocan to deliver a vape battery that have the utmost confidence in.
Recent Insider Transactions • Sep 09Independent Director recently bought CA$81k worth of stockOn the 31st of August, Derek Stern bought around 720k shares on-market at roughly CA$0.11 per share. This transaction amounted to 7.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$232k more in shares than they have sold in the last 12 months.
Reported Earnings • Jul 28Third quarter 2022 earnings released: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021)Third quarter 2022 results: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021). Revenue: CA$10.1m (up 41% from 3Q 2021). Net income: CA$1.43m (down 16% from 3Q 2021). Profit margin: 14% (down from 24% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 28Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)Second quarter 2022 results: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021). Revenue: CA$7.42m (up 229% from 2Q 2021). Net loss: CA$1.15m (loss widened 33% from 2Q 2021).
분석 기사 • Jan 27Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They AppearEven though Cannara Biotech Inc. ( CVE:LOVE ) posted strong earnings recently, the stock hasn't reacted in a large way...
Reported Earnings • Jan 23First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.001 loss per share (up from CA$0.005 loss in 1Q 2021). Revenue: CA$6.56m (up 380% from 1Q 2021). Net loss: CA$530.5k (loss narrowed 85% from 1Q 2021). Revenue was in line with analyst estimates.
공고 • Dec 10Cannara Biotech Inc. Announces New Products LaunchCannara Biotech Inc. Launched two new hash products within the Nugz brand in Quebec retail stores and Old School Hash in a 3-gram bar and Ice Water Hash in a 1-gram temple ball.
분석 기사 • Dec 10Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Dec 10Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.002 loss per share (up from CA$0.017 loss in FY 2020). Revenue: CA$17.3m (up CA$14.7m from FY 2020). Net loss: CA$1.53m (loss narrowed 88% from FY 2020). Revenue was in line with analyst estimates.
Board Change • Dec 06High number of new directorsIndependent Lead Director Don Olds was the last director to join the board, commencing their role in 2020.
공고 • Sep 29Cannara Biotech Inc. Receives Processing and Cultivation LicenseCannara Biotech Inc. announced that it has received the license for cultivation and processing at its one million square foot cultivation and manufacturing facility in Valleyfield, Quebec. The majority of zones in the recently acquired greenhouse are being repurposed as an indoor facility to achieve the same growing conditions as Cannara's Farnham Facility, home of Tribal, Orchid CBD and Nugz. In the Company's first quarter in market, product sales surpassed $7 million with supply capabilities as the limiting factor. This ready build facility will allow the company to fasttrack time to market and will significantly increase product supply bolstering the company's revenues and footprint into new markets.
공고 • Sep 03Cannara Biotech Inc. Receives Amendment of Its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of Its Hash Product Line in QuebecCannara Biotech Inc. announced it has received an amendment of its License from Health Canada, permitting the sale of Cannabis 2.0 products for which the Company intends to use to commercialize hash and other solventless concentrates, solvent-based concentrates, vaporizers, tinctures and topicals. Cannara is excited to announce the first expansion of its Nugz product line: OId School Hash and Ice Water Hash. These two products will first be launched in Quebec and have been specifically formulated for the Quebec market to provide quality hash that contains less than 30% THC. Both products are expected to be available to consumers in the Fall and will be offered in rotating genetics to provide a choice of flavours, terpenes and cannabinoid concentrations from the company's library of rare strains. Nugz Old School Hash is a traditional hash produced using age-old sieving methods and drawn from rare cannabis strains, dry-sifted, gently heated, and pressed into a consistent, sticky, malleable resin. Old School Hash will be available in three-gram bars. Nugz Ice Water Hash is a bubble hash derived from carefully selected single-source THC and CBD indoor-grown whole bud, extracted through ice water to deliver true-to-strain terpene profiles. Ice Water Hash will be available in one gram temple balls. Cannara reaches new Canadians through expansion to Ontario and Saskatchewan. Building on its success in the Quebec market, Cannara has expanded to Ontario and Saskatchewan, extending its reach to a new segment of consumers and marking a significant milestone in the Company's mission to become a leading Canadian cannabis producer. Dried flower and pre-roll products from Cannara's existing Tribal and Nugz lines are currently available at cannabis retailers across Saskatchewan, with the existing Tribal, Orchid CBD and Nugz product lines expected to launch in Ontario starting mid-September 2021.
Reported Earnings • Jul 30Third quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.003 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$7.16m (up CA$6.40m from 3Q 2020). Net income: CA$1.70m (up CA$4.07m from 3Q 2020). Profit margin: 24% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.
공고 • Jun 25+ 1 more updateCannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc.Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million on June 10, 2021. Pursuant to the agreement, Cannara Biotech will have deposited the full CAD 27 million into escrow prior to the close of the sale. Additional CAD 5.7 million deposit to be refunded to Medican upon completion of the transfer to Cannara of a utility pricing agreement with Hydro Quebec, to occur concurrently with Closing. The acquisition will be financed by a non-brokered private placement of up to CAD 35,000,000. The acquisition was financed through non-brokered private placements of CAD 19.3 million resulting in the issuance of 107,222,222 new common shares in the capital of Cannara at a price of $0.18 per share and CAD 5.7 million in the form of an unsecured convertible debenture bearing interest at 4% per annum. The sole subscriber to the Offerings is Olymbec Investments Inc. The transaction closing is subject to usual and customary conditions. Sale expected to close on or before June 22, 2021. The Green will use net proceeds to eliminate senior term debt. BMO Capital Markets acted as financial advisor and Langlois Lawyers LLP acted as legal counsel for The Green Organic Dutchman Holdings Ltd., parent of Medican Organic Inc. Cannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc. on June 23, 2021.
공고 • Jun 11Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million.Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million on June 10, 2021. Pursuant to the agreement, Cannara Biotech will have deposited the full CAD 27 million (the “Purchase Price”) into escrow prior to the close of the sale. Additional CAD 5.7 million deposit to be refunded to Medican upon completion of the transfer to Cannara of a utility pricing agreement with Hydro Quebec, to occur concurrently with Closing. The acquisition will be financed by a non-brokered private placement of up to CAD 35,000,000. The transaction closing is subject to usual and customary conditions. Sale expected to close on or before June 22, 2021. The Green will use net proceeds to eliminate senior term debt. BMO Capital Markets acted as financial advisor and Langlois Lawyers LLP acted as legal counsel for The Green Organic Dutchman Holdings Ltd., parent of Medican Organic Inc.
분석 기사 • Mar 16Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Feb 01First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.004 loss in 1Q 2020)First quarter 2021 results: Net loss: CA$3.50m (loss widened 28% from 1Q 2020).
분석 기사 • Jan 22Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?Cannara Biotech Inc. ( CSE:LOVE ) shareholders will doubtless be very grateful to see the share price up 81% in the...
분석 기사 • Dec 18Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Reported Earnings • Dec 17Full year 2020 earnings released: CA$0.017 loss per shareFull year 2020 results: Net loss: CA$12.5m (loss widened 1.4% from FY 2019).
공고 • Nov 14Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021.
공고 • Nov 06Cannara Biotech Inc. Appoints Donald Olds to Board of DirectorsCannara Biotech Inc. announced the appointment of Donald Olds as a Director on the Company's board of directors. Donald Olds is an experienced life sciences executive, entrepreneur and director with significant experience raising capital for private and public technology companies. Most recently, he was President and Chief Executive Officer of Montreal-based NEOMED Institute.
